Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

An Observational Study of Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) Who Switched IOP-lowering Treatments

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Allergan
ClinicalTrials.gov Identifier:
NCT01735214
First received: November 26, 2012
Last updated: July 25, 2014
Last verified: July 2014

November 26, 2012
July 25, 2014
March 2013
April 2014   (final data collection date for primary outcome measure)
Change from Baseline in Intraocular Pressure (IOP) [ Time Frame: Baseline, 12 Weeks ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01735214 on ClinicalTrials.gov Archive Site
  • Patient Assessment of Tolerability with New Treatment Using a 4-Point Scale [ Time Frame: 12 Weeks ] [ Designated as safety issue: No ]
  • Physician Assessment of Tolerability with New Treatment Using a 4-Point Scale [ Time Frame: 12 Weeks ] [ Designated as safety issue: No ]
  • Percentage of Patients Who Discontinue the Use of New Treatment Prior to 12 Weeks [ Time Frame: 12 Weeks ] [ Designated as safety issue: No ]
  • Percentage of Patients who Continue the New Treatment After 12 Weeks [ Time Frame: 12 Weeks ] [ Designated as safety issue: No ]
  • Physician Assessment of Adherence to New Treatment Using a 4-Point Scale [ Time Frame: 12 Weeks ] [ Designated as safety issue: No ]
  • Physician Assessment of Efficacy Using a 5-Point Scale [ Time Frame: 12 Weeks ] [ Designated as safety issue: No ]
  • Percentage of Patients Reaching Individual IOP Target After 12 Weeks [ Time Frame: 12 Weeks ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
An Observational Study of Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) Who Switched IOP-lowering Treatments
Not Provided

This study is a prospective, observational study of changing from any IOP-lowering treatment to a prostaglandin analogue-containing IOP-lowering medication for patients with Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT). The decision to change medications lies with the physician according to their standard practice.

Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

POAG or OHT

  • Glaucoma, Open-Angle
  • Ocular Hypertension
Drug: Prostaglandin Analogue -Containing IOP-Lowering Therapy
Patients with POAG or OHT on current IOP-lowering therapy who are prescribed a prostaglandin analogue -containing IOP-lowering therapy by the physician. The decision to prescribe a change in IOP-lowering therapy lies with the physician according to their standard practice.
Patients with POAG or OHT
Patients with POAG or OHT on current IOP-lowering therapy who are prescribed a prostaglandin analogue -containing IOP-lowering therapy by the physician. The decision to prescribe a change in IOP-lowering therapy lies with the physician according to their standard practice.
Intervention: Drug: Prostaglandin Analogue -Containing IOP-Lowering Therapy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
402
April 2014
April 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosis of primary open angle glaucoma (POAG) or ocular hypertension (OHT)
  • Previously prescribed any IOP-lowering therapy which has been stopped and a new prostaglandin analogue -containing IOP-lowering therapy started

Exclusion Criteria:

  • None
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Turkey
 
NCT01735214
MAF/AGN/OPH/GLA/037
No
Allergan
Allergan
Not Provided
Study Director: Medical Director Allergan
Allergan
July 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP